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Abstract
Introduction Somatic alterations have been shown to correlate
with breast cancer prognosis and survival, but less is known
about the effects of common inherited genetic variation. Of
particular interest are genes involved in cell cycle pathways,
which regulate cell division.
Methods We examined associations between common
germline genetic variation in 13 genes involved in cell cycle
control (CCND1,  CCND2,  CCND3,  CCNE1,  CDK2  [p33],
CDK4, CDK6, CDKN1A [p21, Cip1], CDKN1B [p27, Kip1],
CDKN2A  [p16],  CDKN2B  [p15],  CDKN2C  [p18], and
CDKN2D [p19]) and survival among women diagnosed with
invasive breast cancer participating in the SEARCH (Studies of
Epidemiology and Risk factors in Cancer Heredity) breast
cancer study. DNA from up to 4,470 women was genotyped for
85 polymorphisms that tag the known common polymorphisms
(minor allele frequency > 0.05) in the genes. The genotypes of
each polymorphism were tested for association with survival
using Cox regression analysis.
Results The rare allele of the tagging single nucleotide
polymorphism (SNP) rs2479717 is associated with an
increased risk of death (hazard ratio = 1.26 per rare allele
carried, 95% confidence interval: 1.12 to 1.42; P = 0.0001),
which was not attenuated after adjusting for tumour stage,
grade, and treatment. This SNP is part of a large linkage
disequilibrium block, which contains CCND3,  BYSL,  TRFP,
USP49,  C6ofr49,  FRS3, and PGC. We evaluated the
association of survival and somatic expression of these genes in
breast tumours using expression microarray data from seven
published datasets. Elevated expression of the C6orf49
transcript was associated with breast cancer survival, adding
biological interest to the finding.
Conclusion It is possible that CCND3 rs2479717, or another
variant it tags, is associated with prognosis after a diagnosis of
breast cancer. Further study is required to validate this finding.
Introduction
Excluding non-melanoma skin cancer, breast cancer is the
most common cancer in the UK, with 36,939 new cases diag-
nosed in 2004 [1]. The prognosis of breast cancer is generally
good, with an overall 5-year survival rate of approximately 80%
in England and Wales [2]. Clinical stage at diagnosis,
CI = confidence interval; ECRIC = Eastern Cancer Registration and Information Centre; ER = estrogen receptor; HR = hazard ratio; LD = linkage 
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including tumour size, lymph node status, and presence of
metastases, along with tumour biological factors such as his-
tological grade and type are the most important determinants
of prognosis [3].
Cyclins and their regulators, which are involved in cell cycle
control, are important as potential oncogenes or tumour sup-
pressor genes in breast cancer [4]. The cell cycle consists of
a series of well-controlled events that drive DNA replication
and cell division. These events are divided into specific
phases: preparation for DNA synthesis (G1), DNA synthesis
(S), a gap phase (G2), and mitosis (M). Transition between
these phases requires tight control; the G1/S phase transition,
in particular, includes many cell cycle events that are altered in
breast cancer [5]. Somatic alterations in these genes have
been shown to correlate with breast cancer prognosis and
survival [6-13], but few studies have examined the effects of
inherited genetic variation in cell cycle genes. The a870g pol-
ymorphism of the CCND1 gene (rs603965) has been shown
to be associated with breast cancer survival in a large Chinese
population-based study [14] and in a small population of
patients with metastatic breast cancer [15]. The V109G poly-
morphism of the p27 gene CDKN1B (rs2066827), examined
by polymerase chain reaction analysis of tumour specimens,
was associated with shortened disease-free survival in a sub-
set of patients with infiltrating metastasis-free breast cancer
[16].
These previous studies, however, were only of selected single
nucleotide polymorphisms (SNPs), and the genes involved in
the G1 phase of cell cycle control have not been systematically
evaluated. The purpose of this study was to assess whether
common germline genetic variation in these genes is associ-
ated with breast cancer survival by using a comprehensive
SNP tagging approach to efficiently capture the common var-
iation. Thirteen genes involved in the G1 phase of the cell cycle
have been investigated in this study, including those that
encode for the cyclin family that regulate cyclin-dependent
kinases (CCND1, CCND2, CCND3, and CCNE1); cyclin-
dependent kinases, which are necessary for the G1/S transi-
tion (CDK2 [p33], CDK4, and CDK6); and cyclin-dependent
kinase inhibitors (CDKN1A  [p21, Cip1], CDKN1B  [p27,
Kip1], CDKN2A [p16], CDKN2B [p15], CDKN2C [p18], and
CDKN2D [p19]).
Materials and methods
Study population
Cases were selected from the Studies of Epidemiology and
Risk factors in Cancer Heredity (SEARCH) breast cancer
study, an ongoing population study of women diagnosed with
breast cancer in the region of England included in the Eastern
Cancer Registration and Information Centre (ECRIC) (formerly
the East Anglian Cancer Registry). Eligible participants
include women diagnosed with invasive breast cancer who
were either under 70 years of age since the beginning of the
study on 1 July 1996 (incident cases) or age 55 or younger
since 1 January 1991 and who were alive at the start of the
study (prevalent cases). Due to boundary changes, some prev-
alent cases diagnosed before 1995 were identified by the
North Thames Cancer Registry.
Of those eligible, 67% returned a comprehensive epidemio-
logical questionnaire and 64% returned a blood sample for
genotyping. All participants in the study provided informed
consent, and the study was approved by the Eastern Multicen-
tre Research Ethics Committee. DNA is available from 4,470
cases for genotyping; 27% of these participants are prevalent
cases.
The samples have been split into two sets in order to save
DNA and reduce genotyping costs. Cases with high genomic
yield were randomly selected from the first 3,500 recruited to
comprise set 1 (n = 2,270), with set 2 comprising the remain-
der of these plus the next 970 incident cases recruited (n =
2,200). DNA yield was not associated with genotype for those
cases included in set 1 or set 2. SNPs showing a positive
association with survival after a diagnosis of breast cancer (P
trend < 0.05) were genotyped in set 2. Data from both sets
were then combined (n = 4,470) to jointly analyze the SNPs
with positive associations. This joint analysis approach results
in increased power to detect genetic association despite more
stringent significance levels with Bonferroni correction [17].
As the prevalent cases were the first recruited, the proportion
of prevalent cases was somewhat higher in set 1 than set 2
(33% versus 20%). In total, 1,370 prevalent cases were
included in both sets; median time from diagnosis to blood
draw was 3.4 years (range: 0.8 to 9.34 years). Median age at
diagnosis was similar in the two sets (50 and 53 years old,
respectively). Median time from diagnosis to blood draw was
slightly longer for set 2 (18 months) than for set 1 (9 months),
but the number of deaths in each set was similar (359 in set 1
and 278 in set 2). There was no significant difference in the
morphology, histopathological grade, or TNM (tumour, node,
metastasis) stage [18] of the cases by set or by prevalent/inci-
dent status.
Participant follow-up
The ECRIC and the North Thames Cancer Registry have
active follow-up at years 3 and 5 after diagnosis and then at 5-
year intervals. Follow-up information and all-cause mortality are
obtained by searching hospital information systems for recent
visits. If a patient has not had a recent visit, the patient's gen-
eral practitioner is contacted to obtain the vital status. Death
certificate flagging through the Office of National Statistics
also provides the registries with notification of deaths. The lag
times with this process are a few weeks for cancer deaths and
2 months to a year for non-cancer deaths. Cause-specific mor-
tality was obtained from part I of the death certificate.Available online http://breast-cancer-research.com/content/10/3/R47
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Gene/single nucleotide polymorphism selection
Thirteen genes involved in the G1 phase of cell cycle regulation
were selected as candidate genes for breast cancer survival.
A comprehensive SNP tagging approach was used in which
tagging SNPs (tagSNPs) were chosen to capture all known
common genetic variation in each gene with an estimated cor-
relation coefficient (r2) of greater than 0.8. In some cases,
SNPs that were poorly correlated with other single SNPs
could be efficiently tagged with a haplotype defined by multi-
ple SNPs. Correlation between these SNPs and the haplotype
of tagSNPs (r2
s) was aimed to be greater than 0.8. TagSNPs
were identified with the program Tagger [19]. Data from the
International HapMap Project [20] and resequencing data
from the National Institute of Environmental Health Sciences
(NIEHS) Environmental Genome Project [21] were used to
select tagSNPs. In total, 85 tagSNPs were chosen.
Genotyping
Genotyping was carried out using the TaqMan®  platform
(Applied Biosystems, Foster City, CA, USA) according to the
manufacturer's instructions. Primers and FAM- and VIC-
labeled probes were supplied directly by Applied Biosystems
as Assays-by-Design™. All assays were carried out in 384-well
plates. Each plate included negative controls (with no DNA)
and positive controls duplicated on a separate quality control
plate. Plates were read on the ABI Prism 7900 using
Sequence Detection Software (Applied Biosystems). Failed
genotypes were not repeated. Assays in which the genotypes
of duplicate samples did not show greater than 95% concord-
ance were discarded and replaced with alternative assays with
the same tagging properties. Call rates for each assay were
over 95%.
Statistical methods
Cox regression analysis was performed to determine the effect
of each tagSNP on survival. The proportional hazards assump-
tion was evaluated by visual inspection of log-log plots as well
as tested analytically using Schoenfeld residuals. TagSNPs
significantly associated with survival were re-evaluated in a
model adjusted for known breast cancer prognostic factors,
which included age at diagnosis (<40, 40 to 49, 50 to 59, or
>60 years), clinical stage (TNM stage 1, 2, 3, or 4), his-
topathological grade (well differentiated, moderately differenti-
ated, or poorly differentiated), estrogen receptor (ER) status,
and treatment.
Time at risk began on the date of blood sample receipt and
ended on the date of death from any cause or, if death did not
occur, on 30 November 2006. This allows for the difference in
ascertainment of incident and prevalent cases and provides an
unbiased estimate of the relative hazard provided that the pro-
portional hazards assumption is correct. Follow-up was cen-
sored at 10 years after diagnosis as follow-up became less
reliable for each individual after 10 years. A hazard ratio (HR)
was estimated for heterozygous and rare homozygous geno-
types relative to the common genotype. Primary tests used
were a likelihood ratio test (2 degrees of freedom) for hetero-
geneity of risk among the three genotypes (common homozy-
gote, heterozygote, and rare homozygote) and a trend test (1
degree of freedom) based on the number of rare alleles car-
ried. All analyses were performed with Intercooled Stata, ver-
sion 8.2 (StataCorp LP, College Station, TX, USA).
Results
Survival analysis
The characteristics of the SEARCH breast cancer study par-
ticipants for whom genotyping and vital status data were avail-
able are described in Table 1. More than 99% of the cases
were Caucasian. There were 3,263 (73%) cases enrolled as
incident cases and 1,207 (27%) as prevalent cases. No signif-
icant difference in survival hazard was found between the two
groups (P = 0.19). During the 25,049 person-years at risk,
there were 637 deaths before 10 years of follow-up. Five hun-
dred forty-two of these deaths were coded as breast cancer-
specific.
Set 1 analysis
The results of the univariate Cox regression analyses for single
marker tagSNPs are shown in Supplementary Table 1 and for
multimarker tagSNPs in Supplementary Table 2 (Additional
File 1). None of the tagSNPs in CCND1, CCND2, CCNE1,
CDK2,  CDK4,  CDK1A,  CDKN1B,  CDKN2A,  CDKN2B,
CDKN2C, or CDKN2D were significantly associated with all-
cause survival. The trend tests for CCND3  rs2479717,
CCND3 rs9529, and CDK6 rs2079147 were significant at
the 0.05 level (P  = 0.001, 0.006, and 0.02, respectively).
CCND3 rs2479717 and CCND3 rs9529 are highly corre-
lated with each other (r2 = 0.92). In a forced Cox regression
model including both CCND3  rs2479717 and CCND3
rs9529, only CCND3 rs2479717 remained significant (P =
0.029). Therefore, only CCND3  rs2479717 and CDK6
rs2079147 were genotyped in the second set.
Joint analysis
CCND3 rs2479717 remained significant in the joint analysis
(HR per rare allele carried = 1.26, 95% confidence interval
[CI]: 1.12 to 1.42; P = 0.0001) (Figure 1). Data on tumour
grade, TNM stage, and age at diagnosis were available for
80%, 97%, and 100% of the cases, respectively. Only stage
and grade remained significantly associated with survival in
the multivariate model. Radiotherapy, chemotherapy, and adju-
vant hormone therapy treatment data were available for 4,303
(96.3%) cases. Of these, 1,412 (32.8%) underwent chemo-
therapy, 3,006 (69.9%) were treated with adjuvant hormone
therapy, and 3,099 (72.0%) received radiotherapy. Surgical
treatment information was available for 4,194 (93.8%) cases;
of these, 3,840 (91.6%) underwent surgery. The risk associ-
ated with CCND3 rs2479717 was not significantly attenu-
ated after adjusting for tumour stage, grade, radiotherapy,
chemotherapy, adjuvant hormone therapy, and surgery (HRBreast Cancer Research    Vol 10 No 3    Azzato et al.
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per rare allele carried = 1.23, 95% CI: 1.07 to 1.41; P =
0.003). We repeated the analysis in those recruited within 3
years of diagnosis (3,558 individuals), and there were no dif-
ferences in the results for both the univariate analysis (HR per
rare allele carried = 1.28, 95% CI: 1.13 to 1.46; P = 0.0002)
and the multivariate model (HR per rare allele carried = 1.23,
95% CI: 1.07 to 1.42; P = 0.004).
ER status was available for 2,624 (58.7%) cases. Of these,
1,975 (75.3%) individuals had an ER-positive tumour. No dif-
ferences across stage, grade, or ER status are noted across
the rs2479717 genotype (Table 2). If ER status is added to
the multivariate model, the power of the model is somewhat
decreased due to a reduction in sample size, resulting in a
slight attenuation of the HR and loss of significance for
CCND3 rs2479717 (HR = 1.13, 95% CI: 0.94 to 1.35; P =
0.19). The HR for CCND3 rs2479717 was almost the same
for those individuals with an ER-positive tumour (HR per rare
allele carried = 1.13; 95% CI: 0.91 to 1.41) and those with an
ER-negative tumour (HR per rare allele carried = 1.12, 95%
Table 1
SEARCH participant survival characteristics
Set 1 Sets 1 and 2
n = 2,270 n = 4,470
Total time at risk, years 1,3851.47 2,5049.24
Median follow-up, yearsa 7.75 (0.56–10)b 7.45 (0.48–10)b
Median time at risk, years 6.47 (0.10–9.64)b 5.70 (0.03–9.77)b
Median time from diagnosis to study entry, years 0.73 (0.00–8.64)b 1.16 (0.00–9.34)b
Number of deaths 359 637
Annual mortality rate 0.026 0.025
5-year survival rate 0.88 (0.86–0.89)c 0.88 (0.87–0.89)c
Median age at diagnosis, years 50.2 (25–69)b 51.0 (23–69)b
Age at diagnosis, years
<40 212 9.30% 394 8.81%
40–49 753 33.20% 1,331 29.78%
50–59 997 43.90% 1,802 40.31%
60+ 308 13.60% 943 21.10%
Histopathological grade
Well differentiated 434 19.11% 871 19.49%
Moderately differentiated 787 34.67% 1,687 37.74%
Poorly differentiated 504 22.20% 1,019 22.80%
Unknown 545 24.00% 893 19.98%
Morphological type
Ductal 1,674 73.74% 3,316 74.18%
Lobular 351 15.46% 659 14.74%
Other 222 9.78% 455 10.17%
Unknown 23 1.01% 40 0.89%
Clinical stage
1 1,112 48.99% 2,190 48.99%
2 986 43.33% 1,981 44.32%
3 or 4 172 7.58% 194 4.34%
Missing 0 0% 105 2.35%
aFollow-up censored at 10 years. bRange of variable. c95% confidence interval. SEARCH, Studies of Epidemiology and Risk factors in Cancer 
Heredity.Available online http://breast-cancer-research.com/content/10/3/R47
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CI: 0.89 to 1.43); the test for interaction was not significant (P
= 0.97).
Results were consistent for breast cancer-specific mortality
(Supplementary Tables 3 and 4 found in Additional File 2).
Only  CCND3  rs2479717 remained significant in the joint
analysis (HR per rare allele carried = 1.26, 95% CI: 1.11 to
1.44; P = 0.0004). This HR was not attenuated by stage,
grade, and treatment (HR per rare allele carried = 1.21, 95%
CI: 1.04 to 1.40; P = 0.01).
Somatic expression analysis
CCND3 rs2479717 is an a > t intronic alteration approxi-
mately 50 bases downstream from exon 3. It lies in a large link-
age disequilibrium (LD) block on chromosome 6, which
contains seven genes: CCND3,  BYSL,  TRFP,  USP49,
C6ofr49, FRS3, and PGC (Figure 2). To further evaluate the
effect of these genes on breast cancer survival, microarray
gene expression data for seven breast cancer cohorts were
taken from existing literature and public databases (Gene
Expression Omnibus and ArrayExpress) [22-28]. The publicly
available data comprise raw expression data that have been
'normalized'. This usually involves background correction,
quantile normalization, and log transformation. The retrieved
datasets were further normalized, if necessary, by transforming
them onto a common log2 scale and shifting the median of
each array to zero [29].
Study characteristics are included in Table 3. In total, the stud-
ies included tumour samples from 1,241 individuals. All of the
studies contained clinical outcomes; five of the studies had
information on all-cause mortality, and two of the studies had
disease recurrence as an outcome. Most of the studies had a
mix of untreated and treated individuals, with treatment includ-
ing both chemotherapy and/or hormonal therapy. Median age
at diagnosis ranged from less than 53 years to 65 years. The
majority of tumours were ER-positive and medium grade (Sup-
plementary Table 5 found in Additional File 3). Combined, the
datasets provided 9,048 years at risk (median of 7.4 years at
risk) and a total of 384 events.
To test whether a gene's expression is associated with clinical
outcome, we used Cox proportional hazards regression mod-
els. In this context, the HR refers to the proportional increase
in hazard risk per unit increase on a log2 scale of expression
level of the transcript. To attempt to control for study hetero-
geneity, expression data for each gene were analyzed two
ways: a Cox survival model stratified by study (fixed effects)
and a random-effects meta-analysis. Elevated expression lev-
els of the BYSL transcript were significantly associated with
breast cancer survival in a random-effects model (HR = 1.84,
95% CI: 1.10 to 3.08; P = 0.02) (Figure 3a), but the associa-
tion did not reach significance in a fixed-effects model (HR =
1.17, 95% CI: 0.99 to 1.38; P = 0.08). Elevated expression
levels of the C6orf49 transcript were significantly associated
with breast cancer survival in a fixed-effects model (HR = 1.60,
95% CI: 1.18 to 2.16; P = 0.002) and in a random-effects
model (HR = 1.84, 95% CI: 1.11 to 3.05; P = 0.02) (Figure
3b). Expression levels of CCND3, TRFP, USP49, FRS3, or
PGC transcripts were not significantly associated with breast
cancer survival (Supplementary Table 6 found in Additional
File 3).
Discussion
We have evaluated the association of 85 tagSNPs in 13 cell
cycle control genes with survival after a diagnosis of breast
cancer. Previous work has shown that expression of these
genes is associated with breast cancer prognosis; however, to
our knowledge, this is the first study to systematically assess
germline variation in genes involved in controlling the cell cycle
and breast cancer survival.
This study used a two-stage design, with an initial set of 85
tagSNPs genotyped in 2,270 individuals. The top two SNPs,
with a P value of less than 0.05, were genotyped in the second
set of patients (n = 2,200). Because a combined analysis with
adjustment for multiple testing has been shown to increase
power over a replication study, a joint analysis of both sets of
data was performed. One SNP, CCND3 rs2479717, showed
a significant association with survival after a diagnosis of
breast cancer (unadjusted P value = 0.0001). This finding
remains significant after a conservative Bonferroni correction
for multiple testing (P value = 0.0085), and the HR is not sig-
nificantly attenuated after adjusting for stage, grade, and treat-
ment. There was no evidence of association with survival for
polymorphisms in CCND1, CCND2, CCNE1, CDK2, CDK4,
CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C,
and CDKN2D.
Figure 1
Kaplan-Meier survival function by CCND3 rs2479717 genotype Kaplan-Meier survival function by CCND3 rs2479717 genotype. Kap-
lan-Meier survival probabilities for women diagnosed with invasive 
breast cancer in the SEARCH (Studies of Epidemiology and Risk fac-
tors in Cancer Heredity) breast cancer study by rs2479717 genotype 
are shown.Breast Cancer Research    Vol 10 No 3    Azzato et al.
Page 6 of 10
(page number not for citation purposes)
These findings were based on the analysis of all-cause mortal-
ity. This may result in a reduction of statistical power as some
deaths will be unrelated to breast cancer. Breast cancer-spe-
cific mortality was available from death certificates, and the
results were consistent for the breast cancer-specific analysis,
with an identical HR for CCND3 rs2479717. It is worth noting
that cause of death as coded on a death certificate is also
prone to misclassification and subsequent loss of statistical
power.
Our analyses incorporated prevalent cases. It may be thought
that inclusion of prevalent cases may result in a bias of the HR.
However, provided that the Cox proportional hazards assump-
tion holds true, the HR estimate is unbiased. For example,
there is no significant difference between the HRs for CCND3
rs2479717, TNM stage, or histopathological grade when
comparing subjects recruited within 6 months of diagnosis
with those recruited more than 6 months after diagnosis (P =
0.69, 0.90, and 0.42, respectively). Furthermore, our repeated
analyses, including only those individuals recruited within 3
years of their diagnosis, were identical to our full analysis.
CCND3 encodes for cyclin D3, a protein involved in the regu-
lation of the G1/S phase transition. The SNP associated with
survival, CCND3 rs2479717, is in an intron and unlikely to
have a functional effect. However, a functional effect would not
be expected as it was chosen as a tagSNP, not as a functional
SNP. Furthermore, a functional variant tagged by this SNP
may not even alter the function of CCND3; the SNP lies in a
large LD block with several genes that are reasonable candi-
dates for breast cancer survival. PGC encodes for pepsino-
gen C, a proteolytic enzyme involved in digestion, which is
expressed in breast tumours [30]. Higher pepsinogen C
expression is associated with well-differentiated and moder-
ately differentiated breast tumours [31] and has been associ-
ated with longer overall survival in these patients [32,33].
BYSL encodes for bystin, a crucial component protein of an
adhesion molecule complex that is important for the attach-
ment of the embryo to the uterus [34]. This protein is present
in human prostatic carcinoma cells in areas of perineural inva-
sion in an increasing gradient, suggesting a role in perineural
adhesion [35]. C6orf49  encodes for overexpressed breast
tumour protein, a member of the LIM domain (cysteine-rich
double zinc fingers) protein family that is overexpressed in
tumours and has a possible role in cancer differentiation
[36,37]. FRS3 encodes for fibroblast growth factor receptor
substrate 3, a negative regulator in epidermal growth factor
receptor tyrosine kinase signaling pathways [38,39]. USP49
encodes for ubiquitin-specific protease 49, which is involved
in the modification of cellular proteins. Ubiquitin-specific pro-
tease 49 is expressed in samples derived from tumour biop-
sies [40]. TRFP  encodes for TATA-binding protein-related
Table 2
CCND3 rs2479717 genotype frequency across stage, grade, and estrogen receptor status
CCND3 rs2479717 genotype
AA AT TT Missing
Stage
1 1,193 (54.5%) 808 (36.9%) 142 (6.5%) 48 (2.2%)
2 1,031 (52.0%) 753 (38.0%) 145 (7.3%) 54 (2.7%)
3 or 4 90 (46.4%) 82 (42.3%) 17 (8.8%) 5 (2.6%)
Missing 60 (58.8%) 31 (30.4%) 9 (8.8%) 2 (2.0%)
Grade
1 484 (55.4%) 314 (35.9%) 60 (6.9%) 16 (1.8%)
2 889 (52.7%) 658 (39.0%) 104 (6.2%) 36 (2.1%)
3 533 (52.3%) 375 (36.8%) 86 (8.4%) 26 (2.5%)
Missing 468 (52.5%) 327 (36.7%) 63 (7.1%) 34 (3.8%)
Estrogen receptor status
Positive 1,089 (55.1%) 717 (36.3%) 130 (6.6%) 39 (2.0%)
Negative 320 (49.3%) 262 (40.4%) 53 (8.2%) 14 (2.2%)
Missing 965 (52.3%) 695 (37.6%) 130 (7.0%) 56 (3.0%)Available online http://breast-cancer-research.com/content/10/3/R47
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protein, which is associated with an RNA polymerase II-SRB
complex; this complex may regulate class II genes [41].
To further evaluate this LD block, we examined breast tumour
expression of these seven genes using expression microarray
data from seven published datasets. Significant associations
between increased tumour expression levels of BYSL  and
C6orf49 transcripts and breast cancer survival emerged. Dif-
ferences between the microarray datasets, varying outcome
information, and incomplete control of confounding by
prognostic factors may limit interpretation of these findings;
however, we attempted to control for patient and tumour het-
erogeneity between these studies by performing two analyses:
a random-effects and a fixed-effects meta-analysis. Although
the results for BYSL are unclear, both analyses showed con-
sistent associations of elevated tumour expression of the
C6orf49 transcript with survival after a diagnosis of breast
cancer.
Conclusion
Our study has found evidence that tagSNP CCND3
rs2479717, which is found in a genomic region that includes
CCND3 and six other genes, is associated with survival after
a diagnosis of breast cancer. Although our study began as an
evaluation of cell cycle control genes, our significant finding
may actually relate to a gene in LD with CCND3 rs2479717
that is not related to cell cycle control. This is supported by our
findings that elevated tumour expression of the C6orf49 tran-
script, one of the genes in LD with rs2479717, is associated
with breast cancer survival. If our findings can be confirmed in
other studies, further evaluation of this locus to identify the
causal variant would be warranted.
Figure 2
Linkage disequilibrium block surrounding CCND3 rs2479717 Linkage disequilibrium block surrounding CCND3 rs2479717. This 219-kilo-base pair section on chromosome 6 contains the genes CCND3, 
BYSL, TRFP, USP49, C6ofr49, FRS3, and PGC, mapped relative to common single nucleotide polymorphisms on HapMap CEU. Squares indicate 
pairwise r2 on a grayscale (black = 1, white = 0). The position of rs2479717 is denoted by a red asterisk.Breast Cancer Research    Vol 10 No 3    Azzato et al.
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Figure 3
Association of BYSL (a) and C6orf49 (b) breast tumour expression with breast cancer outcome Association of BYSL (a) and C6orf49 (b) breast tumour expression with breast cancer outcome. Forest plots are shown for random-effects meta-
analyses of breast tumour expression of BYSL and C6orf49 evaluated by microarray and association with breast cancer recurrence or death. Study-
specific hazard ratios with confidence intervals and an overall estimate of effect are shown. Grey boxes indicate the weight of study in random-
effects meta-analysis.
Table 3
Microarray study characteristics
Study Institution Outcome Microarray 
platform
Evaluated 
genes
Number of 
samplesa
Total time at 
risk, years
Median time 
at risk, years
Number 
deaths/
recurrences
Blenkiron, et 
al. [22]
Nottingham 
City Hospital 
(Nottingham, 
UK)
All-cause 
mortality
Illumina (San 
Diego, CA, 
USA)
PGC, FRS3, 
C6orf49, 
TRFP, BYSL, 
USP49, 
CCND3
128 1,198.0 11.1 45
Chin, et al. 
[23]
University of 
California at 
San 
Francisco
All-cause 
mortality
Affymetrix 
U133A (Santa 
Clara, CA, USA)
PGC, FRS3, 
C6orf49, 
TRFP, BYSL, 
CCND3
129 822.6 6.0 45
Miller, et al. 
[24]
Uppsala, 
Sweden
All-cause 
mortality
Affymetrix 
U133A
PGC, FRS3, 
C6orf49, 
BYSL, 
CCND3
234 1,927.5 10.2 54
Sørlie, et al. 
[25]
Stanford 
University 
(Stanford, 
CA, USA)
All-cause 
mortality
cDNA BYSL, 
USP49, 
CCND3
76 227.6 2.5 30
Sotiriou, et al. 
[26]
John Radcliffe 
(Oxford, UK)
Disease 
recurrence
Affymetrix 
U133A
PGC, FRS3, 
TRFP, BYSL, 
CCND3
94 709.9 7.3 24b
van de Vijver, 
et al. [27]
The 
Netherlands 
Cancer 
Institute 
(Amsterdam)
All-cause 
mortality
Agilent 
Technologies, 
Inc. (Santa 
Clara, CA, USA)
PGC, FRS3, 
C6orf49, 
BYSL, 
USP49, 
CCND3
295 2,319.8 7.2 79
Wang, et al. 
[28]
Erasmus 
(Rotterdam, 
The 
Netherlands)
Disease 
recurrence
Affymetrix 
U133A
PGC, 
C6orf49, 
FRS3, 
USP49, 
BYSL, 
CCND3
285 1,843.1 7.2 107b
Total 1,241 9,048.4 7.4 384
aWith endpoint data. bDisease recurrence.Available online http://breast-cancer-research.com/content/10/3/R47
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